Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
5.35
-0.10 (-1.83%)
May 5, 2026, 4:00 PM EDT - Market closed
Aptevo Therapeutics Employees
Aptevo Therapeutics had 33 employees as of December 31, 2025. The number of employees decreased by 4 or -10.81% compared to the previous year.
Employees
33
Change (1Y)
-4
Growth (1Y)
-10.81%
Revenue / Employee
n/a
Profits / Employee
-$786,879
Market Cap
6.32M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 33 | -4 | -10.81% |
| Dec 31, 2024 | 37 | -3 | -7.50% |
| Dec 31, 2023 | 40 | -5 | -11.11% |
| Dec 31, 2022 | 45 | -9 | -16.67% |
| Dec 31, 2021 | 54 | -4 | -6.90% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| CollPlant Biotechnologies | 39 |
| BiomX | 20 |
| Cardio Diagnostics Holdings | 17 |
| BioRestorative Therapies | 14 |
| Purple Biotech | 10 |
| Dermata Therapeutics | 9 |
| Akari Therapeutics, | 6 |
| Can-Fite BioPharma | 5 |
APVO News
- 5 weeks ago - Aptevo Provides State of the Business Report and 2025 Financial Results - Accesswire
- 6 weeks ago - Aptevo to Participate in March 2026 Conferences - Accesswire
- 2 months ago - Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50% - Accesswire
- 3 months ago - Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth - Accesswire
- 4 months ago - Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality - Accesswire
- 4 months ago - Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split - Accesswire
- 5 months ago - Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025 - Accesswire
- 6 months ago - Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors - Accesswire